Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Apo-Flecainide, Tambocor
Original Date: 
June 2014
  • Treatment of ventricular and supraventricular tachyarrhythmias
  • PO
    • Avoid concurrent administration with feedings as dairy products (milk, infant formula) may interfere with the absorption of Flecainide
  • 1-3 mg/kg/day divided Q8-12h
  • Titrate dose to clinical response up to a maximum of 8 mg/kg/day or 200 mg/m2/day
  • Allow 3 days between dosage increments to achieve new steady-state and to monitor clinical response

Formula for Body Surface Area (BSA):

Click here for Body Surface Area (BSA)

Dosage adjustment required in renal impairment.  Refer to available references or clinical pharmacist for dosage adjustment. 

Side Effects: 
  • CVS: proarrhythmic effects, QTc prolongation
  • Hematology (rare): granulocytopenia, leukopenia, thrombocytopenia
  • Respiratory: bronchospasm
Parameters to Monitor: 
  • Daily ECG until stable dose (monitoring QRS duration)
  • HR
  • CBC with differential
Reconstitution and Stability: 





- Ferlini M, Colli AM, Bonanomi C, et al.  Flecainide as First-Line Treatment for Supraventricular Tachycardia in Newborns. J Cardiovasc Med (Hagerstown), 2009, 10 (5): 372-5

- Price JF, Kertesz NJ, Snyder CS, et al.  Flecainide and Sotalol: A New Combination Therapy for Refractory Supraventricular Tachycardia in Children < 1 Year of Age.  J Am Coll Cardiol 2002; 39: 517-20

- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 20th Edition. Hudson: Lexi-Comp Inc; 2013

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.